v3.26.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
8 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Oct. 31, 2025
Oct. 31, 2024
Product Information [Line Items]        
FDIC limits per institutions     $ 250,000  
Cash balances     930,000  
Revenues $ 5,868,000 $ 3,098,000 5,199,000 $ 4,620,000
Operating and finance lease obligation $ 65,000   $ 100,000 164,000
Common shares issuable upon the exercise of options and warrants [Member]        
Product Information [Line Items]        
Antidilutive securities excluded from computation of earnings per share 8,207,357   4,265,444  
Common shares issuable upon the exercise of unissued restricted stock [Member]        
Product Information [Line Items]        
Antidilutive securities excluded from computation of earnings per share 290,000   212,500  
Common shares issuable upon the exercise of unvested shares of restricted stock [Member]        
Product Information [Line Items]        
Antidilutive securities excluded from computation of earnings per share 178,333   178,333  
Convertible Debt Securities [Member]        
Product Information [Line Items]        
Antidilutive securities excluded from computation of earnings per share 250,000   250,000  
Common shares issuable upon the future payments [Member]        
Product Information [Line Items]        
Antidilutive securities excluded from computation of earnings per share 50,000   100,000  
Large distributor [Member]        
Product Information [Line Items]        
Revenues $ 638,000   $ 597,000 $ 661,000
Large distributor [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration percentage 10.90%   11.50% 14.30%
Another large distributor [Member]        
Product Information [Line Items]        
Revenues $ 598,000   $ 568,000 $ 556,000
Another large distributor [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration percentage 10.20%   10.90% 12.00%
Large medical pactice group [Member]        
Product Information [Line Items]        
Revenues     $ 741,000  
Large medical pactice group [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration percentage     14.30%  
Customer one [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration percentage 94.00%      
One supplier [Member]        
Product Information [Line Items]        
Concentration percentage 61.00%   72.00%  
Raw material $ 104,000   $ 120,000 $ 135,000
Two supplier [Member]        
Product Information [Line Items]        
Concentration percentage 39.00%   28.00%  
Raw material $ 66,000   $ 45,000